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Abstract
Author Manuscript

Objective—For decades it has been known that the HLA–DRB1 shared epitope (SE) alleles are
associated with an increased risk of development and progression of rheumatoid arthritis (RA).
Recently, the following variations in the peptide-binding grooves of HLA molecules that
predispose to RA development have been identified: Val and Leu at HLA–DRB1 position 11, Asp
at HLA–B position 9, and Phe at HLA–DPB1 position 9. This study was undertaken to investigate
whether these variants are also associated with radiographic progression in RA, independent of SE
and anti–citrullinated protein antibody (ACPA) status.

Author Manuscript

Methods—A total of 4,911 radiograph sets from 1,878 RA patients included in the Leiden Early
Arthritis Clinic (The Netherlands), Umeå (Sweden), Hospital Clinico San Carlos–Rheumatoid
Arthritis (Spain), and National Data Bank for Rheumatic Diseases (US) cohorts were studied.
HLA was imputed using single-nucleotide polymorphism data from an Immunochip, and the
amino acids listed above were tested in relation to radiographic progression per cohort using an
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additive model. Results from the 4 cohorts were combined in inverse-variance weighted metaanalyses using a fixed-effects model. Analyses were conditioned on SE and ACPA status.
Results—Val and Leu at HLA–DRB1 position 11 were associated with more radiographic
progression (meta-analysis P = 5.11 × 10−7); this effect was independent of SE status (metaanalysis P = 0.022) but not independent of ACPA status. Phe at HLA–DPB1 position 9 was
associated with more severe radiographic progression (meta-analysis P = 0.024), though not
independent of SE status. Asp at HLA–B position 9 was not associated with radiographic
progression.
Conclusion—Val and Leu at HLA–DRB1 position 11 conferred a risk of a higher rate of
radiographic progression independent of SE status but not independent of ACPA status. These
findings support the relevance of these amino acids at position 11.

Author Manuscript

The development and course of rheumatoid arthritis (RA) are in part determined by genetic
factors. Although the genetic risk factors underlying RA development and progression of
joint destruction are largely nonoverlapping (1), the genetic variants encoding the so-called
HLA–DRB1 shared epitope (SE) alleles are associated with both the risk of RA
development and the severity of the disease course (2–4).

Author Manuscript

The association of HLA class II with RA has been known for decades. The association
between HLA–DR and RA was first reported in 1976 (5). Subsequent identification of risk
HLA–DRB1 alleles that all shared a similar amino acid sequence at positions 70–74 in the
peptide-binding groove of the HLA–DRB1 molecule led to the formulation of the SE
hypothesis (6). This hypothesis postulates that the SE motif itself may be directly involved
in the pathogenesis of RA by allowing the presentation of an arthritogenic peptide to T cells.
Thus far, these peptides have not been identified. With the identification of anti–citrullinated
protein antibodies (ACPAs) in the late 1990s, it became clear that SE alleles mainly
predispose to ACPA-positive RA (3,7). The relevance of HLA–DRB1 for ACPA-negative
RA was set by the identification of HLA–DRB1*03 (part of the conserved ancestral A1-B8DRB1*03 haplotype) as a risk factor for ACPA-negative RA (8,9).

Author Manuscript

Recently, a further refinement of the association between HLA and RA was proposed by
Raychaudhuri et al (10). Using a case–control design with 5,018 ACPA-positive RA patients
and 14,974 controls, the class I and class II HLA regions were explored. The strongest
association was reported for HLA–DRB1 positions 11 and 13 (which are in high linkage
disequilibrium). The amino acids Val and Leu at position 11 conferred a high risk, and Ser
was protective. These associations were independent of the SE status. Furthermore,
performing further conditional analyses, independent associations were observed for
variants in HLA–B position 9 (Asp predisposed to RA) and HLA–DPB1 position 9 (Phe
predisposed to RA). In a subsequent study using a similar approach, the authors also
investigated 2,406 ACPA-negative RA patients and 13,930 controls (11) and observed that
Leu and Ser at HLA–DRB1 position 11 and Asp in HLA–B position 9 were associated with
an increased risk of ACPA-negative RA.
These risk positions are located in the peptide-binding grooves of the HLA molecules.
Studies of MHC class I and class II in mice have shown that a difference of only one or a
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few amino acids at such a crucial place may result in the presentation of totally different
peptides (12,13). Therefore, the finding that additional amino acids located in the antigenpresenting binding grooves associate with RA development is relevant and hypothetically
may fuel further studies to detect arthritogenic peptides involved in RA susceptibility (10).

Author Manuscript

Because the HLA–DRB1 SE alleles are among the strongest genetic factors for a
progressive disease course, the recent findings of Raychaudhuri et al prompted us to
determine the relevance of the newly identified risk factors for the severity of the course of
RA, measured using radiographic joint damage progression. More specifically, first, we
aimed to investigate whether Val, Leu, and Ser at HLA–DRB1 position 11, Asp at HLA–B
position 9, and Phe at HLA–DPB1 position 9 are associated with radiographic progression
in the total RA population and, if so, whether these effects are independent of the wellknown SE effect (HLA–DRB1 positions 70–74). Second, since the SE alleles predispose to
ACPAs and the SE alleles are not associated with radiographic progression independent of
ACPAs (7,14), we aimed to analyze whether the newly identified associations are
independent of ACPAs. Third, we aimed to evaluate whether Leu and Ser at HLA–DRB1
position 11 and Asp at HLA–B position 9, identified as risk factors for ACPA-negative RA,
are associated with joint damage progression in ACPA-negative RA. To this end, a total of
4,911 sets of radiographs of 1,878 patients with RA in 4 different cohorts were studied.

PATIENTS AND METHODS
Patients

Author Manuscript

Patients were included from the following 4 cohorts: the Leiden Early Arthritis Clinic
(EAC), the Umeå cohort, the Hospital Clinico San Carlos–Rheumatoid Arthritis Cohort
(HCSC-RAC), and the National Data Bank for Rheumatic Diseases (NDB). In all cohorts,
RA was defined according to the American College of Rheumatology 1987 criteria (15).
The characteristics of the patients in each cohort are presented in Supplementary Table 1,
available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/
10.1002/art.39018/abstract. Informed consent was obtained from all patients, and approval
was obtained from the local ethics committee of each study.

Author Manuscript

Leiden EAC—This cohort consisted of 594 Dutch patients with early RA who were
enrolled between 1993 and 2006 (16). The mean ± SD age at diagnosis was 57.0 ± 15.6
years, 67.0% of the patients were women, and 52.8% were ACPA positive (as determined
by anti–cyclic citrullinated peptide 2 [anti–CCP-2] antibody test). Radiographs of the hands
and feet were obtained at baseline and during yearly followup visits. In total 3,121 sets of
radiographs obtained over 7 years of followup were chronologically scored by 1 experienced
reader, who was blinded with regard to any clinical or genetic data, using the Sharp/van der
Heijde score (SHS) (within reader intraclass correlation coefficient [ICC] 0.91). Initial
treatment strategies changed over time. Patients enrolled in 1993–1995 were initially treated
with nonsteroidal antiinflammatory drugs (NSAIDs), patients enrolled in 1996–1998 were
initially treated with hydroxychloroquine or sulfasalazine, and patients enrolled in 1999–
2006 were initially treated with methotrexate.
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Umeå cohort—This Swedish cohort comprised 365 patients with early RA enrolled
between 1995 and 2010. The mean ± SD age at diagnosis was 54.3 ± 14.5 years, 69.6% of
the patients were women, and 71.8% were ACPA positive (as determined by anti–CCP-2
antibody test). At baseline and after 2 years, a total of 687 radiographs of the hands and feet
were obtained and scored using the Larsen score by 2 trained readers as previously
described (17). Treatment strategies differed between 1995–2000, 2000–2005, and 2006–
2010, resulting in less severe radiographic progression in the subsequent treatment periods.

Author Manuscript

HCSC-RAC—This Spanish data set involved 380 patients with early RA, diagnosed
between 1976 and 2011 (18). The mean ± SD age at diagnosis was 53.8 ± 14.2 years, 76.3%
of the patients were women, and 48.6% were ACPA positive (as determined by anti–CCP-2
antibody test). During the first 10 years after disease onset, 564 radiographs of the hands
were obtained and scored with known time-order using the SHS (ICC 0.99). Initial treatment
strategies differed for different inclusion periods. Prior to 1990, patients were initially
treated with NSAIDs, from 1990 to 1999 patients received initial monotherapy with
conventional disease-modifying antirheumatic drugs, from 2000 to 2004 patients received
initial monotherapy regularly and combination therapy rarely, from 2005 to 2009 patients
received initial combination therapy regularly as well as biologic agents, and from 2010 to
2011 patients received tailored treatment.

Author Manuscript

NDB—This data set included 539 patients from the US and Canada who were diagnosed
between 1980 and 1999 (19). The mean ± SD age at diagnosis was 48.6 ± 12.6, 78.5% of the
patients were women, and 79.6% were ACPA positive (as determined by anti–CCP-2
antibody test). One set of hand radiographs was available per patient after a mean disease
duration of 10.1 years (range 1–20 years) and scored according to the SHS (ICC 0.98). No
treatment effects were observed for different periods of diagnosis since all patients
developed RA in eras when early, tailored treatment and the use of biologic agents were
uncommon.
Genotyping

Author Manuscript

For all cohorts, we used SNP2HLA to impute classic alleles and corresponding amino acid
polymorphisms for HLA class I loci (HLA–A, –B, and –C) and class II loci (HLA–DPA1, –
DPB1, –DQA1, –DQB1, and –DRB1) (20). We obtained patient genotypes using an
Illumina Immunochip platform (1,21) and used data collected by the Type 1 Diabetes
Genetics Consortium as a reference (22). The HLA imputation has been described in detail
previously (10,11,20). For the present study, the classic HLA–DRB1 alleles and the amino
acids at HLA–DRB1 position 11, HLA–B position 9, and HLA–DPB1 position 9 were
extracted.
Analyses of the associations between variants and radiographic progression
First, the SE alleles, defined based on HLA–DRB1 positions 70–74 according to the SE
hypothesis (6) (DRB1*0101, *0102, *0104, *0401, *0404, *0405, *0408, *0413, *0416,
*1001, and *1402), were tested in relation to radiographic progression. Subsequently, the
amino acids that were shown to confer risk to develop RA in the study by Raychaudhuri et
al (10) (Val and Leu at HLA–DRB1 position 11, Asp at HLA–B position 9, and Phe at
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HLA–DPB1 position 9) were studied in relation to radiographic progression. Analyses were
done per cohort using an additive model (0, 1, or 2 risk amino acids). Since Val and Leu at
position 11 both conferred increased risk, these were combined (i.e., radiographic
progression in the presence of 0, 1, or 2 Val and/or Leu was studied). Because the SE alleles
and Val or Leu on position 11 are often present together, conditional analyses were
performed allowing us to investigate whether Val and Leu were associated with
radiographic progression independent of the known association between HLA–DRB1 SE
status and radiographic progression. Furthermore, for the SE alleles it is known that the
alleles are not associated with radiographic progression independent of ACPAs; in other
words, the SE alleles are not associated with radiographic progression as such but this effect
is mediated by ACPAs (7,14). To determine whether the same is valid for the newly
identified risk factors, analyses were subsequently adjusted for ACPA status.

Author Manuscript

Previously, the amino acid Ser at HLA–DRB1 position 11 was found to protect against RA
development (10). In this study, the association of Ser (0, 1, or 2 amino acids) with
radiographic progression was analyzed.

Author Manuscript

The above-mentioned analyses of Val and Leu and of Ser at HLA–DRB1 position 11 do not
take into account the polymorphic nature of HLA–DRB1 in which different amino acids
encoded by the same position may have a predisposing or protective effect. It is crucial to
ascertain that the predisposing effect identified is not actually due to the absence of a
protective effect and vice versa. Stratification is the most thorough method to differentiate
between these effects and has been used before to distinguish true effects from the effect of
the absence of other alleles (2,23,24). Therefore, patients were stratified into one of the
following 6 groups: susceptible/susceptible (S/S), susceptible/neutral (S/N), susceptible/
protective (S/P), neutral/neutral (N/N), neutral/protective (N/P), and protective/protective
(P/P). Val and Leu at HLA–DRB1 position 11 were the susceptibility amino acids, Ser at
this position was the protective amino acid, and Asp, Pro, and Gly were the neutral amino
acids. Then the groups of S/S, S/N, and N/N were compared to determine whether the effect
of Val and Leu was truly predisposing and not the result of the concomitant absence of Ser.
Similarly, the groups of P/P, P/N, and N/N were compared to determine whether the effect
of Ser was truly protective and not the result of the concomitant absence of the susceptibility
amino acids Val and Leu.
Finally, we evaluated whether the variants that were reported to predispose to ACPAnegative RA (11) (Leu and Ser at HLA–DRB1 position 11 and Asp at HLA–B position 9)
were associated with radiographic progression in ACPA-negative RA.

Author Manuscript

Statistical analysis
In all data sets, radiographic scores were log-transformed (log(score+1)) to approximate a
normal distribution. The residuals of the used models were normally distributed around the
0-line in all cohorts, indicating a good fit of the models (see Supplementary Figure 1,
available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/
10.1002/art.39018/abstract).
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In the cohorts in which multiple sets of radiographs were obtained over time (EAC, Umeå,
and HCSC-RAC), a multivariate normal regression model for longitudinal data was used
with radiographic scores as outcome (1,25,26). This method takes advantage of the withinperson correlation between repeated measurements; as such the radiographic progression
rates were estimated more precisely in the cohorts with serial radiographs compared to data
sets with one radiograph per patient (for a detailed description, see ref. 26). In the cohort in
which a radiograph set was obtained at a single time point (NDB), the estimated yearly
progression rate was calculated (total SHS/disease duration in years at time of radiograph) to
make the estimates of the progression rates comparable to those in the other data sets. Linear
regression analysis was used with estimated yearly progression as outcome variable. In both
models used, the effect sizes obtained were back-transformed and indicated the fold rate of
joint destruction per year per risk amino acid compared to the reference.

Author Manuscript

In all data sets, adjustments were made for age and sex. In the cohorts that included patients
in periods with different treatment strategies (EAC, Umeå, and HCSC-RAC), analyses were
also adjusted for the inclusion period as proxies for differences in treatment strategies.

Author Manuscript

The individual data sets studied were estimated to be insufficiently powered to find
statistically significant associations when performing conditional analyses. Therefore, the
effect sizes and standard errors of the results from the individual cohorts were combined in
inverse-weighted variance meta-analyses with fixed effects to test the overall association.
This was allowed because the effect sizes obtained for the individual data sets, though
different methods were used to score joint destruction (SHS and Larsen), all represented the
relative increase (without units) of progression in joint destruction per year. The metaanalysis weights the results with a low standard error stronger than the results with a high
standard error, preventing an overrepresentation of less precise data in the outcome.
Subsequently, data sets with smaller 95% confidence intervals had a larger weight in the
meta-analysis. P values less than 0.05 were considered significant. Statistical analysis was
performed using SPSS version 20 and Stata 12.0.

RESULTS
Frequencies of variants

Author Manuscript

The allele frequencies of HLA–DRB1 SE and the amino acids at HLA–DRB1 position 11,
HLA–B position 9, and HLA–DPB1 position 9 in the total population studied are presented
in Figure 1. Of the 6 amino acids possible at HLA–DRB1 position 11, Val, Ser, and Leu
were most prevalent in the total RA population (prevalence of 33.2%, 31.7%, and 14.0%,
respectively). Within the ACPA-positive group of RA patients, Val was the most prevalent
amino acid (41.6%), and within the ACPA-negative group, Ser was the most prevalent
(43.7%). At HLA–B position 9, Tyr was the most prevalent and Asp the least prevalent
amino acid (prevalence of 62.4% and 12.6%, respectively). At HLA–DPB1 position 9, Phe
was the most common amino acid with a prevalence of 74.4%. For HLA–B and HLA–
DPB1, the frequencies of amino acids were similar for ACPA-positive and ACPA-negative
RA.
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First, the association between the HLA–DRB1 SE alleles and radiographic progression was
studied. As expected, the SE alleles were associated with more severe radiographic
progression (P = 6.41 × 10−7 in the fixed-effects meta-analysis of the 4 cohorts) (Figure 2).
When SE and ACPAs were analyzed concomitantly, the significance of the SE alleles was
lost (meta-analysis P = 0.20) and ACPA was still significant (meta-analysis P = 2.22 ×
10−16). The association between the SE alleles and radiographic progression was thus not
independent of ACPAs, suggesting that ACPAs play a role in the causal path of the SE
alleles and radiographic progression.
HLA–DRB1 position 11

Author Manuscript

Patients with the risk amino acids Val and Leu had a higher rate of joint damage
progression; this reached statistical significance in 3 individual cohorts (EAC P = 4.94 ×
10−5, Umeå P = 0.032, and NDB P = 0.013) and in the meta-analysis (P = 5.11 × 10−7)
(Figure 2). To illustrate, the raw radiographic data for RA patients included in the Leiden
EAC are presented in Figure 3. In these patients, the presence of one Val or Leu amino acid
was associated with a 1.033-fold rate of joint destruction per year compared to patients
without these amino acids; this equals a 26% (1.033 to the power 7) higher rate of joint
destruction over 7 years. To further illustrate the effects, RA patients with 1 and 2 Val or
Leu amino acids, respectively, had SHS scores that were 10 and 16.5 points higher than
patients without any Val or Leu amino acids (Figure 3). Conditioning on SE status revealed
an independent association of position 11 with radiographic progression (meta-analysis P =
0.022) (Figure 2). This indicates that Val or Leu on HLA–DRB1 position 11 was associated
with radiographic progression independent of the HLA–DRB1 SE status.

Author Manuscript

In order to determine whether the effect of Val and Leu at position 11 on radiographic
progression was independent of the effect of ACPAs on radiographic progression, analyses
were also adjusted for ACPA status. Similar to the SE alleles, the effect of Val and Leu on
radiographic progression was not independent of ACPA status (meta-analysis P = 0.12).
We next studied amino acid Ser at HLA–DRB1 position 11 in more detail, since this variant
was reported to protect against RA (10). Analysis showed that Ser was associated with a
lower rate of joint destruction (meta-analysis P = 5.99 × 10−3) (Figure 4A).

Author Manuscript

Because of the polymorphic nature of HLA–DRB1 and because predisposing as well as
protective associations of variants encoded by the same position with radiographic
progression were observed, we subsequently performed stratified analyses to distinguish
between true-positive signals (i.e., a truly predisposing variant) and false-positive signals
(i.e., seemingly predisposing but actually caused by the absence of protective variants).
First, the association of Val and Leu was studied when comparing patient groups with S/S,
S/N, and N/N, thus excluding patients with the protective amino acid Ser. Carrying Val and
Leu was still associated with more radiographic progression (meta-analysis P = 0.010)
(Figure 5A), and this association remained after additionally conditioning on SE status
(meta-analysis P = 0.012) (Figure 5B), indicating a truly predisposing association for Val
and Leu with radiographic progression. Furthermore, when performing stratified analysis to
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evaluate the effect of Ser in patients not carrying the predisposing variants Val and Leu (thus
comparing 3 groups of patients: P/P, P/N, and N/N) the protective effect of Ser was lost
(meta-analysis P = 0.48) (Figure 4B). This might suggest that the protective effect of Ser
observed in the total RA population was the consequence of the absence of the predisposing
amino acids Val and Leu rather than a truly protective effect.
HLA–B position 9

Author Manuscript

Because risk factors for RA located outside the HLA–DRB1 region were also identified, we
subsequently studied the association of 2 amino acids that are located elsewhere in the HLA
region. First, the association between amino acid Asp at HLA–B position 9 and radiographic
progression was assessed. No association was observed, neither in the individual cohorts nor
in a meta-analysis (meta-analysis P = 0.43). Also, no tendency for association was observed
(Figure 2) (Figure 3 illustrates the raw radiographic data for HLA–B position 9 in the Dutch
RA patients).
HLA–DPB1 position 9
The other variant that is not located within the HLA–DRB1 region was HLA–DPB1. Amino
acid Phe at position 9 in HLA–DPB1 was significantly associated with more severe
radiographic progression (meta-analysis P = 0.024) (Figure 2) (Figure 3 illustrates raw
radiographic data for RA patients in the EAC). However, after conditioning on SE status, no
significance was obtained (meta-analysis P = 0.093) (Figure 2). Furthermore, when
conditioning the effect of Phe for ACPA significance was lost (meta-analysis P = 0.27).
Predisposing variants within ACPA-negative RA

Author Manuscript

Recently, the amino acids Leu and Ser on HLA–DRB1 position 11 and Asp on B position 9
were identified as risk factors for ACPA-negative RA (11). Associations between these
amino acids and radiographic progression were also studied within the ACPA-negative
subgroup, consisting of 657 patients with 1,877 radiograph sets. No significant results were
obtained for Leu/Ser at HLA–DRB1 position 11 or Asp at HLA–B position 9 (meta-analysis
P = 0.18 and P = 0.28, respectively). Also, the directionality of the effects was diverse
(Figure 6) (see Supplementary Figure 2, available on the Arthritis & Rheumatology web site
at http://onlinelibrary.wiley.com/doi/10.1002/art.39018/abstract).

DISCUSSION

Author Manuscript

This study was undertaken to investigate whether genetic variants at HLA–DRB1 position
11, HLA–B position 9, and HLA–DPB1 position 9, which were recently identified as risk
factors for RA, were also associated with radiographic progression in RA, and whether the
associations were independent of HLA–DRB1 SE status and ACPA status. We observed that
RA patients carrying the amino acids Val or Leu at HLA–DRB1 position 11 had more
severe radiographic progression. Despite linkage between the variants at position 11 and the
HLA–DRB1 SE alleles, the effect of Val and Leu was independent of the known SE effect.
In addition, similar to the SE alleles, the effect of Val and Leu at HLA–DRB1 position 11
was not independent of ACPA. Therefore, the findings of the present study validate the
relevance of these amino acids at position 11 in HLA–DRB1.
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Identifying which variants in the HLA region are associated with the development or course
of RA provides the opportunity to increase the understanding of the mechanisms underlying
the progression of RA. The recent observation that the genetic variants that are associated
with risk of RA development and those that are associated with risk of a progressive course
of RA are largely different suggests that the processes driving disease development and
disease severity are to a large extent dissimilar (1). However, a few genetic variants are risk
factors for both RA development and RA severity, highlighting the importance of the
pathway indicated by these risk factors throughout the disease. One such risk factor is the
presence of the SE alleles encoded by HLA–DRB1 positions 70–74, which act via ACPAs
on disease development and outcome. The findings of the present study demonstrate that
Val and Leu at HLA–DRB1 position 11 are also associated with both the development and
severity of RA as measured by radiographic progression.

Author Manuscript

The hope of the formulation of the SE hypothesis was that it would allow the identification
of the auto-antigens of RA (6). However, thus far, arthritogenic peptides have not been
found. Mouse studies have revealed that small changes in amino acids located within the
antigen-presenting binding site may have large influences on the antigens that are presented
(12,13). The amino acids at position 11 and position 13 are observed to be in very tight
linkage disequilibrium (10); therefore, only the amino acids of position 11 were analyzed.
Future studies will reveal whether taking the amino acids at position 11 and 13 into account
will be helpful in identifying the pathogenic antigens that result in immune activation and
autoantibody production, thereby stimulating disease development or progression.

Author Manuscript

Investigation of the HLA region is challenging due to high linkage disequilibrium. This is
illustrated by the fact that 91.8% of all patients evaluated in the present study that had 0, 1,
or 2 SE alleles also had, respectively, 0, 1, or 2 Val/Leu amino acids at HLA–DRB1 position
11, implying that the observation of an additive value of position 11 was actually based on a
relatively small proportion of patients. In addition, the association between SE and
radiographic progression is strong, providing another reason why large data sets are required
to determine whether other HLA variants have additional effects that are independent of the
SE effect. Thus far, to the best of our knowledge, no studies have been published providing
replication of the results regarding RA susceptibility published by Raychaudhuri et al in
completely independent data sets (10). Also in this respect, the findings of the present study,
though evaluating a different outcome, support the relevance of position 11 on HLA–DRB1.

Author Manuscript

In addition to linkage and power issues, the polymorphic nature of the HLA–DRB1 region
in which the same position can encode for both predisposing and protective variants adds
another level of complexity. To unravel these effects, adjusted multivariable analyses and
stratified analyses can be done. The advantage of adjusting in multivariable analyses is that
it is more powerful than subgroup analyses; however, this is at the cost of possible
disturbing effects due to the assumptions underlying the model and eventual disturbances
due to multicollinearity. In our view, in the present setting, stratified analyses yield the most
conclusive results. We observed that Val and Leu at HLA–DRB1 position 11 were truly
predisposing to more severe disease. In contrast, our data suggested that carrying the amino
acid Ser at the same position was not protective. Although a protective effect was observed
initially, in stratified analyses (excluding the effect of the absence of predisposing effects of
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Val and Leu), Ser was not significantly associated with less severe radiographic progression.
These data might suggest that Ser does not have a protective effect on the severity of
radiographic progression in RA. However, it is also possible that the present study was
insufficiently powered to detect a protective effect of Ser in the subgroup of patients studied.
We cannot discriminate between these two possible explanations, and further studies are
needed to determine the association of Ser with the severity of radiographic progression.
Raychaudhuri et al also defined 16 haplotypes, based on positions 11, 71, and 74 in HLA–
DRB1 (10). We did not perform haplotype analyses, since in our view stratification is
needed to distinguish predisposing or protective haplotypes from the absence of protective
and predisposing haplotypes, respectively, and then subgroups became too small.

Author Manuscript

Within the field of RA susceptibility, it has been notable that Ser has been reported to be
protective against ACPA-positive RA but predisposing to ACPA-negative RA (10,11).
Because of this finding, we also evaluated the association of Ser with progression in the
ACPA-negative subgroup. The presence of Ser in these patients was not associated with the
severity of radiographic progression.
We could not identify an association between Asp at HLA–B9 and radiographic progression.
This position, which is highly correlated with HLA–B*08, is part of the conserved ancestral
A1–B8–DRB1*03 (8.1) haplotype and has been associated with susceptibility to ACPAnegative disease (8,9). In contrast to the undisputed association of DRB1*03 or this
haplotype with susceptibility to ACPA-negative RA, we did not detect an association with
the severity of the disease in RA or in ACPA-negative RA.

Author Manuscript

The presence of Phe at HLA–DPB1 position 9 was associated with the severity of
radiographic progression, but significance was lost (P = 0.093) when conditioning for the
HLA–DRB1 SE status. This might suggest that Phe at HLA–DPB1 is not associated with
radiographic progression independent of the association between SE status and radiographic
progression. Notably, the directionality of the effect of Phe at HLA–DPB1 was similar in all
cohorts, with more severe progression in the patients carrying Phe. Although the linkage
between this position with the HLA–DRB1 SE alleles is less than for HLA–DRB1 position
11 with SE (in our study 32.7% of the patients who had 0, 1, or 2 SE alleles also had,
respectively, 0, 1, or 2 Phe amino acids at HLA–DPB1 position 9), it is possible that our
data were insufficiently powered to find an independent association of Phe with
radiographic progression. The present data do not allow making definite conclusions
regarding HLA–DPB1 and radiographic progression; though if an effect is present, this
effect seems to act in the path of ACPAs, similar to HLA–DRB1.

Author Manuscript

In order to get some indication of the variance in joint destruction explained by the genetic
factors studied, the interindividual variance in joint destruction in the Leiden RA patients at
year 7 was evaluated. The SE alleles explained 4.2% of the variance in joint destruction and
the combination of SE alleles, HLA–DRB1 position 11, HLA–DPB1 position 9, and HLA–
B position 9 explained 4.5%. This is lower than the variance in the risk of ACPA-positive
RA explained by a combination of HLA–DRB1 positions 71, 74, and 11, HLA–DPB1
position 9, and HLA–B position 9, which was reported to be 12.7% (10).
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To conclude, Val and Leu at position 11 in the HLA–DRB1 locus were recently identified as
additional susceptibility factors for ACPA-positive RA. We observed that these amino acids
were also associated with a more severe disease course, an effect that was not independent
of ACPA status. Further 3-dimensional modeling studies or binding assays, such as
described previously by Scally et al (27) are needed to determine whether the present
findings result in novel insights in the consequences of the HLA–DRB1 motif on antigen
presentation and its function as an immune response gene.
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Figure 1.

Frequencies of HLA–DRB1 shared epitope (SE) alleles and the amino acids at HLA–DRB1
position 11, HLA–B position 9, and HLA–DPB1 position 9. Frequencies are expressed as
the percentage of a total of 3,756 alleles/amino acids. Of the 1,878 patients, 69.0% were
positive for the HLA–DRB1 SE (at least 1 SE allele), 71.2% were positive for Val/Leu at
HLA–DRB1 position 11 (at least 1 Val or Leu amino acid), 23.8% were positive for Asp at
HLA–B position 9 (at least 1 Asp), and 93.0% were positive for Phe at HLA–DPB1 position
9 (at least 1 Phe). ACPA = anti–citrullinated protein antibody.
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Figure 2.
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Associations of amino acids at HLA–DRB1, HLA–B, and HLA–DPB1 that are known to
predispose to rheumatoid arthritis (RA) development with radiographic progression in RA.
The yearly radiographic progression rates per risk amino acid in each individual cohort are
shown. P values are from the fixed-effects meta-analyses evaluating the 4 cohorts, which
consisted of a total of 1,878 patients and 4,911 sets of radiographs. Risk amino acids were
defined according to the findings of Raychaudhuri et al (10). For the DRB1 shared epitope
(SE), I2 = 22.9%, P = 0.27, fixed-effects P = 6.41 × 10−7, and random-effects P = 2.01 ×
10−4. For Val/Leu at DRB1 position 11, I2 = 23.0%, P = 0.27, fixed-effects P = 5.11 × 10−7,
and random-effects P = 2.19 × 10−4. For Val/Leu at DRB1 position 11 adjusted for SE
status, I2 = 37.3%, P = 0.19, fixed-effects P = 0.022, and random-effects P = 0.066. For Asp
at B position 9, I2 = 0.0%, P = 0.59, fixed-effects P = 0.43, and random-effects P = 0.43.
For Phe at DPB1 position 9, I2 = 0.0%, P = 0.85, fixed-effects P = 0.024, and random-
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effects P = 0.024. For Phe at DPB1 position 9 adjusted for SE status, I2 = 0.0%, P = 0.90,
fixed-effects P = 0.093, and random-effects P = 0.093. EAC = Early Arthritis Clinic; HCSCRAC = Hospital Clinico San Carlos–Rheumatoid Arthritis Cohort; NDB = National Data
Bank for Rheumatic Diseases; ES = effect size; 95% CI = 95% confidence interval.
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Figure 3.

Radiographic progression in rheumatoid arthritis patients in the Leiden Early Arthritis Clinic
cohort per number of risk alleles or amino acids at HLA–DRB1, HLA–B, and HLA–DPB1.
The median raw and unmodeled Sharp/van der Heijde scores (SHS) during 7 years of
followup of 594 RA patients are shown. The P values obtained by multivariate normal
regression analyses comparing the genotypes in relation to radiographic progression were P
= 5.33 × 10−5 for the DRB1 shared epitope (SE) alleles, P = 4.94 × 10−5 for Val/Leu at
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DRB1 position 11, P = 0.044 for Ser at DRB1 position 11, P = 0.62 for Asp at HLA–B
position 9, and P = 0.036 for Phe at DPB1 position 9.
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Figure 4.
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Association of Ser at HLA–DRB1 position 11 with radiographic progression of rheumatoid
arthritis in the total population and in the subgroup of patients who did not carry any
predisposing Val or Leu amino acids. A, Yearly radiographic progression rates per Ser
amino acid at HLA–DRB1 in the total population. Data are shown for each individual cohort
and for the fixed-effects meta-analyses evaluating the 4 cohorts, consisting of a total of
1,878 patients and 4,911 sets of radiographs. I2 = 0.0%, P = 0.40, fixed-effects P = 5.99 ×
10−3, and random-effects P = 5.99 × 10−3. B, Yearly radiographic progression rates per Ser
amino acid at HLA–DRB1 in the patients who did not carry any predisposing Val or Leu
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amino acids. To determine whether the observed association of Ser with radiographic
progression was truly protective and not due to the concomitant absence of the predisposing
amino acids Val and Leu, analyses were performed within the subgroup of patients not
carrying Val and Leu (thus, patients with 2 copies of Ser, patients with 1 Ser and 1 neutral
amino acid, and patients with 2 neutral amino acids were compared). Data are shown for
each individual cohort and for the fixed-effects meta-analyses evaluating the 4 cohorts,
consisting of a total of 541 patients and 1,477 sets of radiographs. I2 = 9.5%, P = 0.35,
fixed-effects P = 0.48, and random-effects P = 0.56. See Figure 2 for definitions.
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Figure 5.
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Association of Val and Leu at HLA–DRB1 position 11 with radiographic progression in the
subgroup of rheumatoid arthritis patients who did not carry any Ser at position 11 and with
additional adjustment for shared epitope (SE) status. A, Yearly radiographic progression
rates per Val or Leu amino acid at HLA–DRB1 position 11 in patients who did not carry any
Ser at position 11. These analyses were performed to determine whether the observed
association of Val and Leu with radiographic progression was truly predisposing and not due
to the concomitant absence of Ser (thus, patients carrying 2 copies of Val or Leu, patients
with 1 Val or Leu and 1 neutral amino acid, and patients with 2 neutral amino acids were
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compared). Data are shown for each individual cohort and for the fixed-effects metaanalyses evaluating a total of 781 patients and 1,747 sets of radiographs. I2 = 0.0%, P =
0.92, fixed-effects P = 0.010, and random-effects P = 0.010. B, Yearly radiographic
progression rates per Val or Leu amino acid at HLA–DRB1 position 11 in patients who did
not carry any Ser at position 11, adjusted for SE status. I2 = 0.0%, P = 0.90, fixed-effects P
= 0.012, and random-effects P = 0.012. See Figure 2 for definitions.
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Figure 6.

Association of Leu and Ser at HLA–DRB1 position 11 and Asp at HLA–B position 9 with
radiographic progression in anti–citrullinated protein antibody (ACPA)–negative RA. Data
are shown for each individual cohort and for the fixed-effects meta-analyses evaluating the 4
cohorts, consisting of a total of 657 patients and 1,877 sets of radiographs. Risk amino acids
were defined according to the findings of Han et al (11). A, Yearly radiographic progression
rates per risk amino acid Leu or Ser at HLA–DRB1 position 11 in ACPA-negative patients.
I2 = 60.8%, P = 0.054, fixed-effects P = 0.18, and random-effects P = 0.59. B, Yearly
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radiographic progression rates per risk amino acid Asp at HLA–B position 9 in ACPAnegative patients. I2 = 0.0%, P = 0.56, fixed-effects P = 0.28, random-effects P = 0.28. See
Figure 2 for other definitions.
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